"CMX001 to Prevent Cytomegalovirus Disease in Hematopoietic-Cell Transplantation"
NEJM Sep 26
http://www.nejm.org/doi/full/10.1056/NEJMoa1303688
"CONCLUSIONS

Treatment with oral CMX001 at a dose of 100 mg twice weekly significantly reduced the incidence of CMV events in recipients of hematopoietic-cell transplants. Diarrhea was dose-limiting in this population at a dose of 200 mg twice weekly. (Funded by Chimerix; CMX001-201 ClinicalTrials.gov number, NCT00942305.)"